Open AccessSacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors
Author(s) -
Kathleen Fenn,
Kevin Kalinsky
Publication year - 2019
Publication title -
drugs of today
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.418
H-Index - 52
eISSN - 1699-4019
pISSN - 1699-3993
DOI - 10.1358/dot.2019.55.9.3039669
Subject(s) - medicine , triple negative breast cancer , antibody drug conjugate , irinotecan , breast cancer , conjugate , oncology , drug , antibody , pharmacology , monoclonal antibody , cancer research , cancer , immunology , colorectal cancer , mathematical analysis , mathematics
Patients with metastatic triple-negative breast cancer (mTNBC) that has progressed on first-line therapy have a poor prognosis with limited therapeutic options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate (ADC) that has shown promising efficacy in mTNBC. SG is comprised of SN-38, the active metabolite of irinotecan, conjugated via a hydrolyzable linker to the humanized RS7 antibody targeting trophoblast cell surface antigen 2 (Trop-2), a glycoprotein that is expressed at high levels in many epithelial solid tumors. It has received breakthrough therapy status by the U.S. Food and Drug Administration (FDA) for the treatment of patients with pretreated mTNBC. In this review, we summarize available data regarding the pharmacology, pharmacokinetics, safety and efficacy of SG and describe ongoing and future clinical studies investigating this agent.